Allianz Asset Management GmbH Cuts Holdings in The Clorox Company (NYSE:CLX)

Allianz Asset Management GmbH cut its holdings in The Clorox Company (NYSE:CLXFree Report) by 43.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,499 shares of the company’s stock after selling 7,433 shares during the quarter. Allianz Asset Management GmbH’s holdings in Clorox were worth $1,354,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CLX. Norges Bank acquired a new position in Clorox during the fourth quarter worth $128,382,000. Qube Research & Technologies Ltd raised its stake in shares of Clorox by 75.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,130,481 shares of the company’s stock worth $148,161,000 after buying an additional 487,974 shares during the last quarter. International Assets Investment Management LLC boosted its position in shares of Clorox by 17,658.5% in the 4th quarter. International Assets Investment Management LLC now owns 484,453 shares of the company’s stock worth $69,078,000 after buying an additional 481,725 shares in the last quarter. Acadian Asset Management LLC grew its stake in Clorox by 39.6% in the 3rd quarter. Acadian Asset Management LLC now owns 1,467,713 shares of the company’s stock valued at $192,319,000 after acquiring an additional 415,999 shares during the last quarter. Finally, FMR LLC increased its holdings in Clorox by 17.4% during the 3rd quarter. FMR LLC now owns 2,415,054 shares of the company’s stock valued at $316,517,000 after acquiring an additional 357,964 shares in the last quarter. Institutional investors and hedge funds own 78.53% of the company’s stock.

Clorox Trading Up 0.4 %

Shares of CLX opened at $132.97 on Monday. The company has a debt-to-equity ratio of 9.73, a current ratio of 0.90 and a quick ratio of 0.53. The Clorox Company has a 12 month low of $114.68 and a 12 month high of $169.14. The stock has a market cap of $16.51 billion, a PE ratio of 68.90, a P/E/G ratio of 2.05 and a beta of 0.39. The stock’s 50-day moving average is $139.82 and its two-hundred day moving average is $144.56.

Clorox (NYSE:CLXGet Free Report) last released its quarterly earnings results on Tuesday, April 30th. The company reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.33 by $0.38. Clorox had a return on equity of 302.49% and a net margin of 3.33%. The firm had revenue of $1.81 billion during the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter in the prior year, the business earned $1.51 EPS. Clorox’s quarterly revenue was down 5.3% compared to the same quarter last year. Equities analysts forecast that The Clorox Company will post 5.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on CLX shares. The Goldman Sachs Group began coverage on Clorox in a research report on Friday, March 1st. They set a “sell” rating and a $140.00 price objective for the company. Citigroup cut their target price on shares of Clorox from $155.00 to $150.00 and set a “neutral” rating for the company in a research note on Wednesday, May 1st. Evercore ISI decreased their price target on shares of Clorox from $145.00 to $142.00 and set an “underperform” rating on the stock in a research note on Wednesday, May 1st. UBS Group cut their price objective on shares of Clorox from $164.00 to $159.00 and set a “neutral” rating for the company in a research report on Wednesday, May 1st. Finally, Jefferies Financial Group upgraded shares of Clorox from an “underperform” rating to a “hold” rating and set a $145.00 target price on the stock in a research report on Tuesday, March 26th. Four analysts have rated the stock with a sell rating and fourteen have issued a hold rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $146.43.

Get Our Latest Research Report on CLX

Clorox Company Profile

(Free Report)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Recommended Stories

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.